Medscape

DMTs Significantly Cut Risk of Long-Term Disability in Primary Progressive MS

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...
Monthly Prescribing Reference

Fenebrutinib Reduces Relapses in RMS, Slows Disability Progression in PPMS

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...
MedPage Today

Ocrelizumab Shows Hand Function Benefits in Advanced Progressive MS

Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
Medscape

Ocrelizumab Shows Benefit in Advanced MS: Phase 3 Data

BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...
Monthly Prescribing Reference

Tolebrutinib Misses Primary Endpoint in Phase 3 PPMS Study

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...